Personalized Therapy in a Case of Esophageal NEC Based on Tumor Genome Sequencing
Introduction: High-grade esophageal neuroendocrine carcinomas (NEC) constitute a rare subgroup of neuroendocrine neoplasms, with a particularly aggressive behaviour and unfavourable prognosis. To date, there are no validated biomarkers for personalized therapy and cytotoxic chemotherapy remains the standard of care. However, tumor genome sequencing may help improve NEC molecular landscape knowledge in order to identify novel targets for an individualized approach.
Aim(s): To report a case of esophageal NEC treated according to its molecular profile.
Materials and methods: Tumor comprehensive genomic profiling through FoundationOne CDx test was performed.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: La Salvia A
To read the full abstract, please log into your ENETS Member account.